|
Summary of causes of death in placebo-controlled clinical trials1 |
||
| Drotrecogin alfa (activated; n [%]) |
Placebo (n [%]) |
|
|
|
||
| Cause of death category |
||
| Sepsis-induced multiorgan failure |
113 (47.9) |
107 (39.2) |
| Refractory septic shock |
49 (20.8) |
65 (23.8) |
| Respiratory failure |
32 (13.6) |
51 (18.7) |
| Myocardial infarction |
9 (3.8) |
11 (4.0) |
| Primary cardiac arrhythmia |
6 (2.5) |
9 (3.3) |
| Hemorrhage |
4 (1.7) |
1 (0.4) |
| Intracranial hemorrhage |
2 (0.8) |
1 (0.4) |
| Stroke |
2 (0.8) |
7 (2.6) |
| Other |
19 (8.1) |
21 (7.7) |
| Total deaths |
236 (100) |
273 (100) |
|
The drotrecogin alfa (activated) groups comprised 940 and the placebo groups 881, yielding a total of 1821 patients. 1 F1K-MC-EVAA and F1K-MC-EVAD (PROWESS). | ||
Bernard et al. Critical Care 2003 7:155 doi:10.1186/cc2167 |
||